(Press-News.org) CHICAGO, IL (April 3, 2012)––Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3.
"It's an exciting time to be involved in lymphoma treatment and research," says study author Mitchell Smith, M.D., Ph.D., director of Lymphoma Service at Fox Chase. "There's a new understanding of the disease, and new drugs to treat it. I am optimistic that over the next couple of years treatments will continue to get even better and less toxic."
During the study, Smith and his colleagues investigated a compound known as TL32711 (Birinapant), developed by TetraLogic Pharmaceuticals in Malvern, Pennsylvania. The compound works by blocking the process cells used to avoid death, he explains—in other words, it inhibits the process that inhibits cell death. "TL32711 is like a double-negative. It inhibits the inhibitor, and therefore makes cells more sensitive to dying."
To test whether TL32711 works better in some types of lymphomas than others, Smith and his team added it to various lymphoma cells. Since compounds tend to work best when given in combination with other drugs, in some cells they added another compound known as TRAIL, which targets tumor cells.
The researchers found that some types of lymphoma appeared more vulnerable to the effects of TL32711, suggesting these patients should be the first to try the finished product in clinical trials. Specifically, they saw that follicular lymphoma cells and some types of diffuse large B cell lymphomas were more likely to die following treatment. Not surprisingly, adding TRAIL to the mix appeared to make TL32711 even more effective at killing lymphoma cells. "We saw the combination worked better than either one alone," says Smith.
Importantly, the researchers saw the cells didn't just die—they died because of the action of the compounds, explains Smith. TL32711 works by enhancing cell death—known formally as apoptosis—and just before cells experience apoptosis, they activate proteins known as caspases. Sure enough, after exposure to the compounds, the level of active caspases increased, confirming the cells were undergoing more apoptosis. "This result confirms that the cells are dying the way they should when you add these compounds," says Smith.
TL32711 is not yet available in the clinic, says Smith, but already some clinical trials are enrolling patients to test its effects. He and his colleagues plan to continue to test the compound in animals, to get a better sense of how it should best be used in humans.
"We're getting a much better understanding of why lymphoma cells don't die," he adds. "We're starting to see drugs that hit different pathways in the cell. Our research is about trying to take the compounds that target this particular pathway forward in the most efficient way possible."
INFORMATION:
Dr. Smith's co-authors include Indira Joshi at Fox Chase Cancer Center, along with colleagues from TetraLogic Pharmaceuticals.
This work was supported in part by funding from TetraLogic Pharmaceuticals.
Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).
END
CHICAGO – The addition of a screening ultrasound or magnetic resonance imaging (MRI) to annual mammography in women with an increased risk of breast cancer and dense breast tissue resulted in a higher rate of detection of incident breast cancers, according to a study in the April 4 issue of JAMA.
"Annual ultrasound screening may detect small, node-negative breast cancers that are not seen on mammography. Magnetic resonance imaging may reveal additional breast cancers missed by both mammography and ultrasound screening," according to background information in the article. ...
CHICAGO – Although data indicate that between 2003-2009 there was a substantial decline in the U.S. in hospitalizations for pneumonia and inpatient deaths, analysis suggests that trends in documentation and diagnostic coding, rather than improvements in actual outcomes, may explain much of the observed changes, according to a study in the April 4 issue of JAMA.
Pneumonia is a leading cause of illness and death among U.S. adults, resulting in more than 1 million annual hospital admissions and accounting for more than $10.5 billion in aggregate costs. "Given its public ...
CHICAGO – Adding the drug cetuximab to a regimen of drugs used for the treatment of patients following surgery for stage III colon cancer did not result in improved disease-free survival, according to a study in the April 4 issue of JAMA.
Patients who have surgery for removal of stage III colon cancer have a 50 percent chance of cure. Multiple trials have established the benefit of chemotherapy after surgery in reducing the recurrence risk. "Specifically, [the drugs] leucovorin, fluorouracil, and oxaliplatin (FOLFOX or slightly different method, FLOX) provides significant ...
CHICAGO – In an analysis of a cohort that included nearly one million patients who had visited an ophthalmologist, patients who were taking oral fluoroquinolones had a higher risk of developing a retinal detachment, a serious eye condition, compared with nonusers, although the absolute risk was small, according to a study in the April 4 issue of JAMA.
"Fluoroquinolones are one of the most commonly prescribed classes of antibiotics. Their broad-spectrum antibacterial coverage and high-tissue distribution provide potency for a wide variety of community-acquired infections," ...
CHICAGO --The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
The findings were announced during the American Association for Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago.
"The most important finding is that this approach is feasible and we are encouraged by preliminary evidence that this approach may ...
Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs.
Besides their deadly consequences, pancreatic cancer and heart disease share a connection with genetic pathways that control cholesterol and a cell signaling system known as the Hedgehog pathway. (The name refers to the shape of its mutated protein in fruit flies, ...
In a research article published April 3 in the online, open-access journal PLoS Biology, Prof. Sylvia Cremer and colleagues at the Institute of Science and Technology, Austria show how micro-infections promote social vaccination in ant societies. Like crowded megacities, ant colonies face a high risk of disease outbreaks. These are kept in check by the ants' social immune system—a set of collective hygienic behaviours and adaptive changes in interaction frequencies that acts in conjunction with the physiological, innate immune system of colony members. Prof. Cremer and ...
Top executives at Anago Cleaning Systems hosted its 2012 annual conference for their Master Franchisees in an effort to celebrate major growth and successes in 2011, and prepare for aggressive expansion and improvement throughout each territory and the nation. New and existing Master Franchisees alike attended the two-day show that was held on March 5-6, 2012 in Orlando, Florida.
The convention kicked off with opening remarks from Anago Cleaning Systems Founder, David Povlitz.
Mr. Povlitz reiterated that the vision, mission, and values of the company he founded in ...
An international team of scientists has created an innovative tool for teaching the fundamentals of epidemiology—the science of how infectious diseases move through a population.
The team teaches a workshop annually in South Africa that helps epidemiologists improve the mathematical models they use to study outbreaks of diseases like cholera, AIDS and malaria. Led by Steve Bellan from the University of California at Berkeley, the team created a new game as a teaching aid for the workshop. The exercise, which has proven extremely effective in demonstrating concepts in ...
Genetic mutations in cancer cells can lead to resistance to treatment, thereby potentially resulting in relapse. However, a new article, published April 3 in the magazine section of the online, open-access journal PLoS Biology, suggests that the converse may also happen. Steven Frank from the University of California, Irvine, and Marsha Rosner from the University of Chicago, propose that it may often be the case that a few cells become resistant before any genetic change, and then later acquire the genes to stabilize that resistance.
Why does it matter whether resistance ...
